Cocrystal Pharma Announces the Publication by Collaborators of Positive Data Demonstrating Potent In Vitro Inhibition Against Coronavirus in Science Translational Medicine Journal
04 août 2020 08h05 HE
|
Cocrystal Pharma, Inc.
– Cocrystal has two exclusive licenses for the coronavirus protease inhibitors described in the publication – – Cocrystal is currently further conducting preclinical studies of these coronavirus...
Cocrystal Pharma Reports First Quarter 2020 Financial Results and Provides Updates on Antiviral Programs
14 mai 2020 07h05 HE
|
Cocrystal Pharma, Inc.
- Company has sufficient capital to advance pipeline and fund operations through 2021 - BOTHELL, WA, May 14, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc (NASDAQ: COCP), (“Cocrystal” or the...
Cocrystal Pharma Provides COVID-19 Impact Update on Development Programs
11 mai 2020 08h05 HE
|
Cocrystal Pharma, Inc.
– Company reprioritizes activities to accelerate development and provides next steps for advancing preclinical COVID-19 Coronavirus program – – Discussions ongoing with potential strategic...
Cocrystal Pharma Expands Exclusive License Agreement with Kansas State University Research Foundation to New Coronavirus Antiviral Compounds with Novel Mechanism of Action
22 avr. 2020 08h05 HE
|
Cocrystal Pharma, Inc.
- Expanded license agreement with KSURF further broadens and advances Cocrystal’s COVID-19 program - - Small molecule therapeutic inhibitors against coronaviruses included in agreement have...
Cocrystal Pharma Announces Appointment of Nobel Laureate and Scientific Advisor, Roger D. Kornberg, Ph.D., to Board of Directors
20 avr. 2020 08h05 HE
|
Cocrystal Pharma, Inc.
- Work completed over decades of renowned biochemist’s career serves as basis for Company’s structure-based technology which has demonstrated broad utility in development of proprietary antivirals - ...
Cocrystal Pharma to Present at the April 2020 Virtual Investor Summit
15 avr. 2020 08h05 HE
|
Cocrystal Pharma, Inc.
– Presentation with live audio webcast on Wednesday, April 22 at 11:00 AM ET, immediately followed by an interactive Q&A session – BOTHELL, WA,, April 15, 2020 (GLOBE NEWSWIRE) -- Cocrystal...
Cocrystal Pharma Reports 2019 Financial Results and Outlines Expected Value-Driving Milestones for 2020
30 mars 2020 06h05 HE
|
Cocrystal Pharma, Inc.
Advancing preclinical COVID-19 Coronavirus program leveraging patent rights recently acquired from Kansas State University Research Foundation (“KSURF”) Continuing collaboration with Merck to discover...
Cocrystal Pharma Announces Closing of $6.8 Million Registered Direct Offering Priced At-the-Market
11 mars 2020 09h40 HE
|
Cocrystal Pharma, Inc.
BOTHELL, WA, March 11, 2020 (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel...
Cocrystal Pharma Announces $6.8 Million Registered Direct Offering Priced At-the-Market
09 mars 2020 15h00 HE
|
Cocrystal Pharma, Inc.
BOTHELL, WA, March 09, 2020 (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel...
Cocrystal Pharma Announces Plans to Advance Coronavirus Program
06 mars 2020 16h01 HE
|
Cocrystal Pharma, Inc.
Company has immediately initiated Coronavirus programLeveraging patent rights recently acquired from Kansas State University Research Foundation (“KSURF”) Strong financial position bolsters Company’s...